東曜藥業-B(01875.HK)出售100萬股順天醫藥股份
格隆匯12月7日丨東曜藥業-B(01875.HK)發佈公吿,於2021年12月7日,公司與晟德大藥廠訂立過户書,據此公司同意出售且晟德大藥廠同意購買100萬股順天醫藥股份,按每股順天醫藥股份新台幣36.5元的價格以總代價新台幣3650萬元以場外大宗交易方式進行。
順天醫藥生技為一間台灣臨牀階段生物製藥公司,致力於神經系統疾病以及炎症等疾病領域的新藥開發,在手研發的主要產品包含類鴉片止痛劑,以及治療急性缺血性中風的創新藥物。其股份於台北櫃買中心上櫃(股份代號:6535)。
出售事項結算及交割後,集團將不再持有任何順天醫藥股份。待售股份乃公司持有多年的長期股權投資。公司決定出售待售股份,以集中資源為集團的持續營運資金需求(尤其是其研發開支)提供資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.